Qureight Partners with Mediar Therapeutics to Deploy AI-Powered Imaging Analytics in Phase 2 Systemic Sclerosis Trial
核心洞察
Qureight (搜索) will provide AI-powered 3D quantitative imaging analytics to support Mediar Therapeutics (搜索)' Phase 2 EncompaSSc trial evaluating MTX-474 in diffuse cutaneous systemic sclerosis (搜索).
The collaboration will utilize Qureight (搜索)'s comprehensive imaging models including Glass8™, Fibr8™, Vascul8™, Air8™, and Lung8™ to assess compartment-specific lung biomarkers and therapeutic response.
MTX-474 is a first-in-class monoclonal antibody targeting EphrinB2 (搜索), a key protein driving fibrosis (搜索) in systemic sclerosis (搜索), addressing a critical unmet need in this high-mortality disease.
Qureight (搜索), a specialized imaging contract research organization, has announced a strategic partnership with clinical-stage biotechnology company Mediar Therapeutics (搜索) to support the Phase 2 EncompaSSc trial of MTX-474 in patients with diffuse cutaneous systemic sclerosis (搜索) (dcSSc). The collaboration will leverage Qureight's AI-powered 3D quantitative imaging analytics platform to evaluate changes in compartment-specific lung biomarkers during treatment with the investigational monoclonal antibody therapeutic.
Advanced Imaging Analytics for Complex Disease Assessment
Systemic sclerosis (搜索) is a complex autoimmune disease characterized by fibrosis (搜索), vasculopathy, and inflammation affecting the lungs, skin, and other vital organs. The disease is associated with high morbidity and mortality, creating a critical need for new therapeutics that can effectively halt disease progression.
During the EncompaSSc trial, Qureight (搜索) will analyze High-Resolution Computed Tomography (HRCT) images of participants' lungs taken at screening and at 24 weeks after treatment with MTX-474. The company's platform will deploy multiple specialized imaging models to provide comprehensive disease assessment:
- Glass8™ for assessment of inflammatory signal
- Fibr8™ for quantification of fibrotic lung change
- Vascul8™ for evaluation of pulmonary vascular alterations
- Air8™ for airway analysis
- Lung8™ for comprehensive lung structural assessment
These AI-driven models work together to provide detailed compartment-specific understanding of disease activity and therapeutic response in systemic sclerosis (搜索), generating immediate results from highly detailed analyses that enable more sensitive, rapid, and efficient insights into disease stabilization or progression compared to traditional image-based analysis.
First-in-Class Therapeutic Targeting Fibrosis
MTX-474 represents a novel approach to treating systemic sclerosis (搜索) as a first-in-class human monoclonal antibody designed to inhibit EphrinB2 (搜索), a key protein that drives fibrosis (搜索) in the disease. This protein mediator of myofibroblast activation accelerates fibrosis in systemic sclerosis, making it an attractive therapeutic target.
The EncompaSSc trial is a randomized, double-blind, placebo-controlled study designed to investigate the safety and efficacy of MTX-474 in people with dcSSc. The study will enroll participants who will be randomly assigned in a 3:2 ratio to receive MTX-474 or matching placebo by intravenous infusion. Treatment will be administered every four weeks, with treatment response assessed at a 12-week interim analysis and an end-of-treatment visit at week 24.
Industry Perspectives on Advanced Imaging Integration
"We're proud to have been selected by Mediar Therapeutics (搜索) to support this important systemic sclerosis (搜索) study," commented Jessica Payne, Chief Commercial Officer at Qureight (搜索). "Our AI-powered imaging platform delivers analysis beyond traditional metrics, providing precise, compartment-specific insights into lung disease. Together, these AI-driven biomarkers offer a powerful approach to understanding disease activity and progression in systemic sclerosis."
Jeff Bornstein, Chief Medical Officer at Mediar Therapeutics (搜索), emphasized the strategic value of the collaboration: "We are dedicated to changing the landscape of treatment approaches for fibrotic diseases, including systemic sclerosis (搜索), to drive real impact on patient outcomes. We are excited to work with Qureight (搜索) on this Phase 2 trial of MTX-474, building on the success in Phase 1. Qureight's AI-driven imaging endpoints provide deeper insights into lung fibrosis (搜索) in complex diseases, such as Systemic Sclerosis."
The partnership represents a significant advancement in the application of AI-powered imaging analytics to evaluate therapeutic response in fibrotic diseases, potentially setting new standards for precision endpoint assessment in systemic sclerosis (搜索) clinical trials.